Biomolecular Diagnostics News and its predecessor, Nano/Bio Convergence News cover the increasing use of molecular diagnostics in drug discovery, in medical diagnosis and genetic testing, in environmental testing, and in food safety. We present news items under topics such as: Biomarkers, Genomics, Proteomics, Microarrays, Imaging, Nanodiagnostics, Patents and Licensing, and Industry News.
For instance, in 2003, under the topic Biomarkers, we reported on Celera Diagnostics' discovery of several novel genetic markers associated with an increased risk for myocardial infarction (MI), or heart attack. These will eventually join the natiuretic peptide assays by Roche Diagnostics and Biosite used to diagnose congestive heart failure, as molecular diagnostics becomes a standard part of cardiology.
Under Genomics, we reported that Cepheid's amplification technology was included in anthrax sensors that will be installed widely by the U.S. post office to protect postal workers. These sensors are the vanguard of what eventually will be widely distributed environmental molecular sensors that, in time, will outnumber security cameras, to protect us from not only from bioterror, but also from natural horrors like SARS, Nipah virus, avian flu, and environmental toxins.
Microarray News included NimbleGen Systems' introduction of a human whole genome long oligo array to measure the whole human transcriptome on a single chip. Not to be outdone, introduced the Mapping 10K Array for whole genome SNP analysis. Applied Biosystems Group, for its part, completed the development of the genetic variation map based on single nucleotide polymorphisms (SNPs). Over 150,000 SNP genotyping assays were used to characterize 180 DNA samples from African-American, Caucasian, Chinese, and Japanese individuals to create a human genome-wide genetic variation map.
Nanodiagnostics is starting to make a big splash. Evident Technologies commenced shipment of its EviTags quantum dot labels for biotechnology applications. The water-soluble dots come in five colors with two different reaction groups for conjugation. Quantum Dot Corp also released quantum dot reagents for molecular assays and was involved as a collaborator in a number of spectacular studies that used quantum dots as stable fluorescent tags in living cells and organisms. As of March 2004, Quantum Dot reported that it has over 1,000 customers for these interesting reagents worldwide.
Under Industry News, we reported on the continuous consolidation in the diagnostics industry. One of the more interesting mergers was GE Medical's purchase of Amersham plc, in recognition that molecular imaging will be increasingly important as a diagnostic modality. Roche Diagnostics bought out IGEN International in a not-exactly-friendly transaction. Roche determined that it was easier to buy IGEN outright than to pay all the royalties it would owe after a U.S. Court of Appeals decided in IGEN's favor in a patent infringement suit. Invitrogen continued its acquisition binge, gorging itself on Molecular Probes and Genicon Sciences, among others.
Looking forward, we predict continued success for the molecular diagnostic industry. Never in the history of the world have so many chronically ill people walked the planet. And most of us are getting older. Demographics and explosion of proteomic and genomic information concerning disease states are the major dynamics that are driving the industry.
Need a custom data table, graph, region, segment, companies or complete report?
CUSTOMIZE NOW
Let us assist you! Our analysts are ready to tailor this report to your specific need.
REACH OUT TO US TODAY
Published - Jul-2003|
Analyst - Review |
Code - BIO001D
Published - May 2024 |
Publisher - BCC Publishing |
Code - BIO077F
The global market for companion diagnostics is estimated to increase from $7.6 billion in 2023 to reach $15.4 billion by 2028, at a compound annual growth rate (CAGR) of 15.2% from 2023 through 2028.
Published - May 2024 |
Publisher - BCC Publishing |
Code - BIO149E
The global market for exosome diagnostics, therapeutics and research tools is estimated to increase from $227.5 million in 2023 to reach $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 2028.
Published - May 2024 |
Publisher - Partha Sarathi Das |
Code - BIO252A
The global market for peptide synthesis is expected to grow from $90.1 billion in 2023 and projected to reach $157.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.8% during the forecast period of 2023 to 2028.
The global market for oligonucleotides is expected to grow from $7.0 billion in 2023 and projected to reach $11.7 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2023 to 2028.
The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028.
Published - Nov 2022 |
Publisher - BCC Publishing |
Code - BIO208B
The global market for cell and gene therapy tools and reagents is estimated to grow from $8.3 billion in 2022 to $13.7 billion in 2027, with a compound annual growth rate (CAGR) of 10.6% for the period of 2022-2027.
Published - Dec 2022 |
Publisher - BCC Publishing |
Code - ENV056A
This report focuses on the ESG trends in the chemical industry and evaluates the ESG implementation including current and future potential. The report utilizes various databases, including sustainability reports, annual reports, and other indicators used to develop the current market. The study provides detailed information on the main factors influencing ESG growth in the chemical industry. It enables the reader to understand the industry in general while also providing insight into the inter-relationship between ESG and the sustainable chemical industry. The report describes market growth, developing trends, industry leaders, and applications of ESG implementation in the chemical industry.
Published - Dec 2022 |
Publisher - BCC Publishing |
Code - HLC161D
The global digital pathology market is estimated to increase from $5.9 billion in 2022 to reach $10.7 billion by 2027, at a compound annual growth rate (CAGR) of 12.5% from 2022 through 2027.
Published - Nov 2022 |
Publisher - BCC Publishing |
Code - HLC285A
The global smartphone-based patient monitoring market should reach $21.5 billion by 2027 from $6.8 billion in 2022 at a compound annual growth rate (CAGR) of 25.9% for the forecast period of 2022 to 2027.
Published - Nov 2022 |
Publisher - BCC Publishing |
Code - IFT248A
The global NFTs market should reach $37.6 billion by 2022 and $125.6 billion by 2027, with a compound annual growth rate (CAGR) of 27.3% during the forecast period of 2022-2027.
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.